Thompson Grace, Pepperell Dominic, Lawrence Ian, McGettigan Benjamin David
Department of Immunology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
Department of Haematology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
BMJ Case Rep. 2017 Feb 22;2017:bcr2016218578. doi: 10.1136/bcr-2016-218578.
We report a case of Epstein-Barr virus (EBV)-driven haemophagocytic lymphohistiocytosis (HLH) in a man with Crohn's disease treated with 6-mercaptopurine and adalimumab therapy who was successfully treated with rituximab therapy alone. This is the first published case in an adult patient with EBV-driven HLH in the setting of thiopurine use and inflammatory bowel disease to be successfully treated with rituximab therapy alone. Here, we will discuss putative immunological mechanisms which may contribute to this potentially life-threatening complication.
我们报告了一例由爱泼斯坦-巴尔病毒（EBV）驱动的噬血细胞性淋巴组织细胞增生症（HLH），患者为一名患有克罗恩病的男性，正在接受6-巯基嘌呤和阿达木单抗治疗，仅通过利妥昔单抗治疗即获得成功。这是首例已发表的成年患者，在使用硫唑嘌呤和患有炎症性肠病的情况下发生EBV驱动的HLH，仅通过利妥昔单抗治疗即获得成功。在此，我们将讨论可能导致这种潜在危及生命并发症的假定免疫机制。
